tumor necrosis factor-␣; Sp1; mitogen-activated protein kinase THE AIRWAY EPITHELIUM is the first layer of cellular interaction with airborne antigens and plays a key role in initiating allergic responses (45, 46) . The airway surface liquid, often referred to as mucus, is a thin layer of fluid covering the luminal surface that plays an important defensive role against foreign particles entering the lung. Removal of inspired particles occurs by the combined action of adherence to mucus and cilia beating (mucociliary clearance). The principle protein constituents of airway mucus are the highly hydrated mucin (MUC) glycoproteins (designated MUC in humans, Muc in animals). Currently, 20 MUC genes have been identified and their encoded glycoproteins classified as gel-forming, secreted, or cell-associated mucins (12, 23, 35) . Gel-forming mucins (MUC2, 5AC, 5B, 7, and 8) are produced by respiratory epithelial cells and likely account for the viscoelastic property of the mucus layer. MUC1, 4, 13, and 16 are transmembrane glycoproteins localized on the surface of airway epithelial cells.
MUC1 was the first member of the mucin gene family to be cloned (13) . MUC1 expression is polarized to the apical surface of most simple epithelia, as well as uniformly on hematopoietic cells. MUC1 is unique among the membranebound mucins because its cytoplasmic region possesses a canonical receptor tyrosine kinase-like structure, particularly with respect to the presence of phosphoamino acid sequence motifs mediating signal transduction cascades (5, 12) . Phosphorylation of the MUC1 cytoplasmic tail (CT) at serine, threonine, and tyrosine residues has been extensively characterized (22, 23, 43, 44) . Although the role of MUC1 in airway cell physiology remains to be determined, a recent study by our group (25) demonstrated that MUC1 exhibits anti-inflammatory properties in the airways, suggesting that it may be involved in resolving ongoing immune responses.
We previously reported that primary hamster tracheal epithelial cells abundantly express Muc1 protein on their surface (30, 31) and that Muc1-expressing cells exhibited increased adhesion of Pseudomonas aeruginosa by virtue of a specific interaction of the Muc1 extracellular region with flagellin, the major structural protein of the bacterial flagellum (20, 21) . P. aeruginosa is a gram-negative opportunistic pathogen responsible for a wide range of acute and chronic pulmonary infections, particularly in patients with cystic fibrosis or who are mechanically ventilated, elderly, or immunosuppressed. Patients with P. aeruginosa lung infections mount an inflammatory response characterized by airway mucin hypersecretion, lung neutrophilia, and high levels of proinflammatory cytokines. Prominent among the latter is tumor necrosis factor (TNF)-␣, which is produced by diverse cell types including macrophages, lymphocytes, fibroblasts, and epithelial cells (2, 24) . Following binding to the TNF receptor (TNFR), TNF-␣ activates multiple intracellular signal transduction cascades culminating in a diverse array of biological responses (9) . Noteworthy in this regard, TNF-␣ upregulates MUC1 expression in epithelial cells derived from airway, breast, prostate, and uterine tissues (17, 29, 38, 41) . In the case of respiratory cells, Shirasaki et al. (38) reported that TNF-␣ increased MUC1 mRNA levels in human primary nasal epithelial cells. However, no studies have been reported examining the effects of TNF-␣ on MUC1 expression in cells derived from the lower airways.
The purpose of this study was twofold: 1) to determine whether TNF-␣ induced MUC1 expression in A549 cells, a human lung carcinoma (19) , and if so, 2) to elucidate the mechanism involved. Our results demonstrated that TNF-␣ increased the expression of MUC1 in A549 cells at both the mRNA and protein levels, and this effect was mediated through a TNFR1 3 MEK1/2 3 ERK1 3 Sp1 pathway. We speculate that TNF-␣ plays a dual role during microbial infection of the airways, serving as a proinflammatory cytokine during the initial stages of the immune response, followed by an anti-inflammatory effect as a consequence of upregulation of MUC1 expression.
METHODS
Cell culture. A549 cells were seeded in RPMI 1640 medium containing 10% FBS (Invitrogen, Carlsbad, CA) and 25 mM HEPES in 24-well plates at 5.0 ϫ 10 4 cells/well and cultured to confluence at 37°C, 5% CO2. Mouse tracheal surface epithelial (MTSE) cells were harvested and cultured on 12-mm Millicell inserts (Millipore, Billerica, MA) at an air-liquid interface as described for rat TSE cells (26) .
MUC1 immunoblotting and immunoprecipitation. A549 cells were washed with PBS, pH 7.4 at 4°C, and extracted with 1.0 ml/100-mm dish of PBS, 1.0% Triton X-100, 1.0% sodium deoxycholate, and 1.0% protease inhibitor cocktail (Sigma, St. Louis, MO). Lysates were incubated for 20 min at 4°C, and insoluble material was removed by centrifugation at 14,000 g for 10 min at 4°C. Protein concentrations were measured using the bicinchoninic acid method with BSA as a standard (Bio-Rad, Hercules, CA). Equal protein aliquots were resuspended in SDS-PAGE Laemmli buffer (0.05 M Tris ⅐ HCl, pH 6.8, 2.5% ␤-mercaptoethanol, 1.0% SDS, 5% glycerol, and 0.1% bromphenol blue), boiled for 5 min, and resolved on 6% (for the extracellular domain) or 15% (for the CT domain) acrylamide gels. Resolved proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad) for 1 h at 100 V in 0.02 M Tris ⅐ HCl, pH 8.3, 0.19 M glycine, and 20% methanol, and the membrane was blocked for 30 min at room temperature with 5% BSA (Sigma)/TBS-T (0.01 M Tris ⅐ HCl, pH 7.4, 0.15 M NaCl, and 0.1% Tween 20) . Membranes were reacted overnight at 4°C with either the MUC1-reactive monoclonal antibody GP1.4 (20 g/ml; Biomeda, Foster City, CA) to detect the extracellular subunit or rabbit CT33 antiserum (1: 10,000) to detect the CT subunit. CT33 was prepared against a synthetic peptide corresponding to the COOH-terminal 17 residues of the MUC1 CT subunit and is identical in reactivity to the MUC1 CT1 (32) and CT2 (7) antibodies. Identical dilutions of purified normal mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were used as negative controls. Following incubation, the membranes were washed three times with TBS-T, reacted 1 h at room temperature with horseradish peroxidaseconjugated secondary antibody (goat anti-mouse IgG or goat antirabbit IgG; KPL, Gaithersburg, MD), washed three times, and developed with enhanced chemiluminescence reagents (Amersham-Pharmacia, Piscataway, NJ). The bands corresponding to the MUC1 extracellular (Ͼ250 kDa) and CT (25 kDa) protein subunits were identified by comigration of prestained protein size markers (BioRad). For MUC1 immunoprecipitation, 0.5 mg of cell lysate was reacted overnight at 4°C with 10 l of CT33 antiserum. Bound proteins were isolated with 50 l of protein A-agarose (Invitrogen) and analyzed by immunoblotting. The CT33 antibody heavy chain was detected as a gel loading/transblot efficiency control using antirabbit IgG antibody.
Effect of TNF-␣ on MUC1 mRNA expression. Confluent A549 cells were treated for 0, 4, 8, or 24 h with 0, 10, 25, 50, or 100 ng/ml of purified human recombinant TNF-␣ (ProSpec, Rehovot, Israel) or vehicle control (PBS), and MUC1 mRNA was quantified by real-time RT-PCR. In experiments to determine MUC1 mRNA stability, the cells were treated for 24 h with 50 ng/ml TNF-␣, chased for 0, 4, 8, or 24 h with 5.0 g/ml actinomycin D (Sigma), and washed with PBS, and MUC1 mRNA levels were quantified.
Real-time RT-PCR. Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA), and 0.2 g was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad) in a total volume of 20 l. Real-time PCR was carried out using TaqMan probes and iQ supermix (Bio-Rad) according to the manufacturer's instructions. Briefly, 2.0 l of cDNA or control plasmid were used as template for amplification in the iCycler (Bio-Rad) with 200 nM of MUC1 or GAPDH (internal control) primers and probes. Primers and probes were designed using Beacon Designer 2.0 software (Biosoft, Palo Alto, CA). The MUC1 forward primer was 5Ј-TCAGCTTCTACTCT-GGTGCACAA-3Ј, and the reverse primer was 5Ј-ATTGAGAATG-GAGTGCTCTTGCT-3Ј. The MUC1 probe had the fluorescent molecule 6-carboxy-fluorescein (FAM) attached at the 5Ј end and the black hole quencher-1 (BHQ-1) attached to the 3Ј end (5Ј-FAM-TCTGCCAGGGCTACCACAACCC-BHQ-1-3Ј; IDT, Coralville, IA). The GAPDH forward primer was 5Ј-AGCCTCAAGATCATCAG-CAATG-3Ј, and the reverse primer was 5Ј-GTTGTCATGGATGAC-CTTGGC-3Ј. The GAPDH probe had the fluorescent molecule hexachlorofluorescein (Hex) attached at the 5Ј end and BHQ-1 attached to the 3Ј end (5Ј-Hex-CCTGCACCACCAACTGCTTAGCAC-BHQ-1-3Ј). PCR was performed with a 15-s melt at 95°C, followed by annealing for 30 s at 60°C and extension for 30 s at 72°C for 40 cycles. All reactions were performed in triplicate. The C t value was defined as the number of PCR cycles required for the specific fluorescence signal to exceed the detection threshold value set by the software installed in the iCycler. The levels of MUC1 transcripts were normalized to GAPDH transcripts using the 2 Ϫ⌬⌬Ct method. Mitogen-activated protein kinase immunoblot analysis. Confluent A549 cells were serum-starved for 24 h and treated for 0, 5, 10, 20, 30, or 60 min with 50 ng/ml of TNF-␣ at 37°C. Equal protein aliquots of cell lysates were subjected to SDS-PAGE on 12% acrylamide gels and analyzed by immunoblotting with anti-JNK or phospho-JNK, anti-p38 or phospho-p38, or anti-ERK1/2 or phospho-ERK1/2 specific antibodies (Cell Signaling, Beverly, MA). Immunoblotting with anti-␤-tubulin antibody was performed as a gel loading control. In some experiments, the cells were pretreated for 30 min with anti-TNFR1 antibody (R&D Systems, Minneapolis, MN) before TNF-␣ treatment.
Transient transfection and luciferase assay. A549 cells were seeded in RPMI 1640, 10% FBS, and 25 mM HEPES in 24-well plates and incubated for 24 h at 37°C, 5% CO2, to 70 -80% confluence. Medium was replaced with serum-free RPMI 1640 and 25 mM HEPES, and the cells were incubated an additional 24 h. The medium was changed to RPMI 1640, 1% FBS, and 25 mM HEPES, and the cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The DNA sample consisted of 800 ng of a MUC1 promoter-firefly luciferase reporter plasmid (MUC1-pGL2b) (16) or the empty pGL2b vector plus 10 ng of the phRL-TK internal control plasmid encoding Renilla luciferase (Promega). MUC1 promoter deletion-luciferase reporter plasmids were prepared as our group described previously (16) . Briefly, sample DNA was mixed with 2.0 l of Lipofectamine and diluted with OPTI-MEM I (Invitrogen) to a final volume of 100 l. After 20 min of incubation at room temperature, 600 l of the DNA-Lipofectamine mixture was added to each well. At 6 h posttransfection, the cells were washed with RPMI 1640, 1% FBS, and 25 mM HEPES and treated for 24 h at 37°C with 50 ng/ml TNF-␣ or vehicle control. In some experiments, the transfected cells were pretreated for 1 h before TNF-␣ treatment with mithramycin A (Sp1 inhibitor), SB 203580 (p38 inhibitor), JNK inhibitor II, or U0126 (MEK1/2 inhibitor) (Cell Signaling). Luciferase activity was determined using the Dual Luciferase assay system (Promega) according to the manufacturer's instructions and a microplate luminometer (Lmax; Molecular Devices, Sunnyvale, CA). Luciferase activity driven by the MUC1 promoter was normalized to the internal control by calculating the ratio of firefly luciferase activity to Renilla luciferase activity of each sample and expressed as the percentage of MUC1 promoter activity relative to control samples.
Dominant negative ERK1/2 transfection. Dominant negative (DN)
expression plasmids for ERK1 and ERK2 (34) were kindly provided by Dr. Jian-Dong Li (Rochester University, Rochester, NY). A549 cells were serum-starved for 24 h and transfected for 6 h as described above with ERK1 DN, ERK2 DN, or pcDNA3.1 vectors before treating with TNF-␣ for 12 h. Total RNA was isolated for real-time RT-PCR as described above.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) assay was performed using the ChIP assay kit (Upstate Biotechnology, Lake Placid, NY) with slight modification. Briefly, following treatment with TNF-␣ or PBS, A549 cells were treated with 1% formaldehyde at 37°C for 10 min to cross-link DNA with its binding proteins. The fixed cells were washed with ice-cold PBS and extracted with 200 l/100-mm dish of ChIP lysis buffer (50 mM Tris ⅐ HCl, pH 8.1, 1% SDS, 10 mM EDTA, and 1.0% protease inhibitor cocktail), and the cell lysates were sonicated to shear DNA to an average size of 500 base pairs. After centrifugation, the supernatant was diluted 10-fold with ChIP dilution buffer (16.7 mM Tris ⅐ HCl, pH 8.1, 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 150 mM NaCl, and 1.0% protease inhibitor cocktail), and an aliquot of the diluted sample was kept at 4°C after adjusting the NaCl concentration to 200 mM until used as the input sample. The remainder of the diluted sample was mixed with protein A agarose-salmon sperm DNA (1:1) preincubated at 4°C for 1 h to reduce nonspecific binding, the mixture was centrifuged, and the supernatant was immunoprecipitated with Sp1 antibody (Santa Cruz Biotechnology) or control IgG at 4°C overnight. An aliquot of the protein A agarosesalmon sperm DNA slurry was added to the immunoprecipitated sample, followed by constant mixing at 4°C for 1 h. After centrifugation, the resulting agarose pellet was sequentially washed once with low-salt wash buffer (20 mM Tris ⅐ HCl, pH 8.1, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, and 150 mM NaCl), once with high-salt wash buffer (20 mM Tris ⅐ HCl, pH 8.1, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, and 500 mM NaCl), once with LiCl wash buffer (1 mM Tris ⅐ HCl, pH 8.1, 1% NP-40, 1% deoxycholate, 1 mM EDTA, and 0.25 M LiCl), and twice with 1ϫ Tris-EDTA buffer (10 mM Tris ⅐ HCl, pH 8.0, and 1 mM EDTA). The agarose pellet was incubated at room temperature for 15 min in elution buffer (1% SDS, 0.1 M NaHCO 3, and 10 mM DTT), and the protein-DNA cross-linkages were reversed with 200 mM NaCl for 6 h at 65°C. DNA was extracted with phenol-chloroform, precipitated with ethanol, and subjected to PCR using the MUC1 forward primer 5Ј-TCTTATTTCTCGGC-CGCTCTGCTT-3Ј and the reverse primer 5Ј-TGGGTAGGGTA-CAAGGGCTCTAAT-3Ј. MUC1 amplicons were quantified by densitometry and corrected by background subtraction. Relative intensity values were obtained by normalizing the corrected intensity values to those of the input samples.
Statistical analysis. Differences in mean Ϯ SE values among groups were assessed using the Student's t-test for unpaired samples and considered significant at P Ͻ 0.05. Fig. 1 , TNF-␣ significantly increased MUC1 protein expression in A549 cells compared with PBS-treated cells. MUC1 expression by TNF-␣ was dose dependent, with a maximum response at 50 ng/ml of the cytokine. As shown by densitometry, ϳ10-fold increased MUC1 expression was obtained following TNF-␣ treatment, compared with constitutive MUC1 expression in cells treated with PBS. This effect of TNF-␣ was also observed in primary MTSE cells grown on an air-liquid interface (Fig. 1B) . Although A549 cells were originally derived from a carcinoma, their ability to produce various types of mucins, as well as the technical feasibility to transfect various genes into these cells, made it possible to study the regulation of mucin production and mucous cell metaplasia in vitro, which has resulted in a significant contribution to our current understanding of airway mucin cell biology (35) . Based on the results in Fig. 1B showing a similar response of MTSE cells to that of A549 cells, we used A549 cells for the remainder of the experiments to identify the signaling pathway involved in TNF-␣-induced MUC1 transcription.
RESULTS

TNF-␣ induces MUC1 protein expression in human lung carcinoma cells. As shown in
TNF-␣ increases MUC1 mRNA levels in dose-and timedependent manners. The increase in cellular MUC1 protein content following TNF-␣ treatment could have been due to increased gene transcription, translation, or stability of MUC1 mRNA or protein. To determine the effect of TNF-␣ on MUC1 transcription, A549 cells were treated with various concentrations of TNF-␣ and MUC1 transcript levels were determined using real-time RT-PCR. TNF-␣ significantly increased MUC1 mRNA levels in a dose-dependent manner compared with PBS-treated cells ( Fig. 2A) . At 50 ng/ml, TNF-␣ also significantly increased MUC1 transcripts at all time points examined (Fig. 2B) . This concentration of TNF-␣ is within the physiological range measured in vivo based on a study with human asthmatics (4) .
TNF-␣ does not affect MUC1 mRNA stability. To determine whether TNF-␣ treatment altered MUC1 mRNA stability, A549 cells were treated for 24 h with 50 ng/ml of TNF-␣ and chased in the presence of PBS or actinomycin D to block RNA polymerase activity. As shown in Fig. 3 , MUC1 mRNA levels in cells treated with actinomycin D for 4, 8, or 24 h were identical to those in PBS-treated cells. To verify that the effect of TNF-␣ was to induce MUC1 gene transcription, A549 cells were transfected with a MUC1 promoter-firefly luciferase reporter plasmid (MUC1-pGL2b) and treated with PBS or TNF-␣, and luciferase activity was determined relative to that of cotransfected Renilla luciferase. TNF-␣-treated MUC1-pGL2b-transfected cells exhibited ϳ170% increased luciferase activity compared with PBS-treated cells (Fig. 4) .
TNF-␣ induces MUC1 transcription through ERK1. TNF-␣ is a potent activator of mitogen-activated protein (MAP) kinases (2, 9, 24). As shown in Fig. 5 , the levels of phosphorylated p38, JNK, and ERK1/2 were increased in A549 cells treated with TNF-␣ compared with PBS treatment. Phosphorylation of all three MAP kinases was maximal at 10 min after cytokine treatment and decreased to basal levels by 60 min. Next, to determine which MAP kinase(s) was responsible for TNF-␣-induced MUC1 expression, MUC1-pGL2b-transfected A549 cells were pretreated with selective kinase inhibitors before TNF-␣ treatment, and relative luciferase activity was determined. Only the MEK1/2-specific inhibitor U0126 completely blocked the ability of TNF-␣ to induce MUC1 promoter activity compared with PBS (Fig. 6) . To confirm the involvement of ERK1/2 in this pathway, A549 cells were transfected with ERK1 DN, ERK2 DN, or their control plasmid (pcDNA3.1) before TNF-␣ treatment. As shown in Fig. 7 , TNF-␣-induced MUC1 transcription was completely suppressed Fig. 2 . TNF-␣ induces MUC1 mRNA expression in A549 cells. Confluent A549 cells were serum-starved for 24 h and treated for 6 h with PBS or the indicated concentrations of TNF-␣ (A) or treated with 50 ng/ml TNF-␣ for the indicated time periods (B). Total RNA was analyzed for the levels of MUC1 mRNA by using real-time RT-PCR, and data were normalized to GAPDH mRNA levels. Each data point represents the mean Ϯ SE (n ϭ 3). Data are representative of 3 experiments. *P Ͻ 0.05, significantly increased MUC1 mRNA levels in TNF-␣-treated cells compared with vehicle control (0 ng/ml). with ERK1 DN but not with ERK2 DN. To confirm that the effect of the cytokine was not due to a potential impurity in the TNF-␣ preparation, A549 cells were pretreated with anti-TNFR1 antibody before TNF-␣ treatment, and the levels of phospho-ERK1/2 were determined. As shown in Fig. 8 , anti-TNFR1 antibody completely blocked the ability of TNF-␣ to stimulate ERK1/2 phosphorylation compared with anti-TNFR1 alone. The anti-TNFR1 antibody used in this experiment exhibits a partial TNF-␣ agonist activity in A549 cells according to the manufacturer's description of the antibody. From the collective results presented in Figs. 5-8, we concluded that TNF-␣ stimulated MUC1 expression through TNFR1, MEK1/2, and ERK1.
TNF-␣ induces MUC1 transcription through Sp1. Although the mechanism of transcriptional regulation of the MUC1 gene remains to be completely determined, it is well-known that the Sp1 transcription factor plays a major role downstream of ERK1/2 (14, 16) . Consequently, to determine whether TNF-␣-induced MUC1 transcription involves Sp1, MUC1-pGL2b-transfected A549 cells were pretreated with mithramycin A, a specific Sp1 inhibitor (3), before TNF-␣ treatment, and relative luciferase activity was determined. Mithramycin A (500 nM) completely prevented MUC1 promoter induction by TNF-␣ (Fig. 9A) . No cytotoxicity was observed with this concentration of mithramycin A judging from both cell morphology and cellular lactate dehydrogenase release (data not shown). The Sp1 binding site at Ϫ99/Ϫ90 in the MUC1 promoter is crucial for TNF-␣-induced MUC1 transcription. Ten putative Sp1 binding sites are present in the MUC1 promoter, and our group (16) previously reported that only the site between nucleotides Ϫ99 and Ϫ90 (relative to the transcription initiation site) was required for neutrophil elastase (NE)-induced MUC1 transcription. Based on the report by Sivko et al. (39), we made several deletion mutants and point mutations at positions Ϫ97 and Ϫ96 (GG to AA) (Fig. 9B) to block the binding of Sp1 to this region and determined the effect on TNF-␣-stimulated MUC1 promoter activation. MUC1 promoter activity induced by TNF-␣ was completely abolished in the cells transfected with a deletion mutant that does not contain the putative Sp1 binding site (Fig. 9, B and C) or a point-mutated MUC1 promoter plasmid (Fig. 9C) . These data suggest that the Ϫ99/Ϫ90 Sp1 binding site is the only one that is crucial for MUC1 promoter activity induced by TNF-␣.
TNF-␣ induces Sp1 binding to the MUC1 promoter region in vivo.
To determine whether Sp1 binding to the MUC1 promoter is induced by TNF-␣, we performed a ChIP assay on the MUC1 promoter with Sp1 antibody or control IgG. Sp1-responsive elements in the MUC1 promoter after immunoprecipitation were analyzed by semiquantitative PCR. TNF-␣ significantly induced the binding of Sp1 to the MUC1 promoter region (Fig. 10A ) by 2.3-fold compared with vehicle control (Fig. 10B) .
DISCUSSION
In this study, we demonstrated that MUC1 mRNA and protein synthesis in A549 cells were enhanced by TNF-␣ treatment. Increased MUC1 transcript levels following TNF-␣ treatment were due to increased de novo transcription, not elevated mRNA stability. With the use of a combination of biochemical, pharmacological, and molecular biological approaches, a TNFR1 3 MEK1/2 3 ERK1 3 Sp1 pathway was demonstrated to mediate TNF-␣-induced MUC1 promoter activity. Finally, a specific cis regulatory element located between nucleotides Ϫ99 and Ϫ90 in the MUC1 promoter that possessed a consensus Sp1 binding sequence motif was required for TNF-␣-stimulated MUC1 promoter activation. It is noteworthy that the mechanism described in this study was obtained using a lung adenocarcinoma that may have a different signaling pathway for TNF-␣-induced MUC1 transcription compared with normal airway epithelial cells.
The identification of a MUC1 transcriptional mechanism induced by TNF-␣ corroborates and extends a previous study by our group (18) and others (1, 11) that revealed positive regulatory elements in the MUC1 gene promoter, which contains five putative NF-B and 10 potential Sp1 binding sites. As a mechanism for TNF-␣-induced MUC1 transcription in the presence of IFN-␥, it was demonstrated that binding of NF-B to the MUC1 promoter occurred at nucleotides Ϫ589/Ϫ581 (17) . On the other hand, binding of Sp1 at the Ϫ99/Ϫ90 site was crucial for the regulation of MUC1 transcription (14) . In particular, we previously demonstrated that NE induced MUC1 transcription via Sp1 binding at this same site (16) . On the basis of the present results, increased Sp1 binding to the Ϫ99/Ϫ90 sequence also appears responsible for TNF-␣-induced MUC1 transcription. Five phosphorylation sites on Sp1, either serine or threonine, have been confirmed (6) . Mutation studies revealed a role for Sp1 phosphorylation in DNA binding and promoter activation in mammalian cells (6) . Activated ERK has been shown to be involved in serine or threonine phosphorylation of Sp1, resulting in transcriptional activation of either the urokinase plasminogen activator receptor gene (42) or the vascular endothelial growth factor gene (27) . Therefore, it is possible that increased Sp1 binding to the Ϫ99/Ϫ90 segment of the MUC1 promoter is mediated by Sp1 phosphorylation by ERK. Experiments are underway in our laboratory to delineate the site(s) of Sp1 phosphorylation in the context of ERK-induced MUC1 transcription.
Although we cannot formally rule out the possible involvement of NF-B in TNF-␣-stimulated MUC1 expression, this mechanism appears unlikely by analogy to the effect of NE, where protease-induced MUC1 expression was retained in cells expressing a MUC1 promoter deletion mutant lacking all of the NF-B sites (16) . Thus the detailed mechanism through which TNF-␣ induces increased Sp1 binding to the Ϫ99/Ϫ90 promoter segment remains to be determined. TNF-␣-induced Sp1 phosphorylation may be involved, because it has been shown that Sp1 binding to DNA is enhanced by serine/threonine phosphorylation of the transcription factor (6, 27) . Further investigation of the signaling pathway responsible for MUC1 transcription induced by TNF-␣ is presently in progress in our laboratory.
The current paradigm of airway inflammation dictates that following inhalation and colonization of the lungs by pathogenic microorganisms, respiratory epithelial cells and resident leukocytes become activated to express many different genes, including the proinflammatory cytokines IL-1␤, IL-6, IL-8, and TNF-␣ (15, 33), which attract neutrophils from the circulation into the airways. In particular, IL-1␤ and TNF-␣ induce the transcription of genes necessary to perpetuate the innate immune response that ultimately results in activation and extravasation of neutrophils to the lungs. Accumulated pathogens are killed mainly by neutrophils through phagocytosis, as well as by the release of various antimicrobial products such as NE and reactive oxygen species (46) . Although a plethora of information is available with regard to the pathology of airway A Fig. 10 . TNF-␣ induces Sp1 recruitment to the MUC1 promoter in viable cells. A549 cells (100% confluent) were serum-starved for 24 h and treated with vehicle control or 50 ng/ml TNF-␣ for 1 h at 37°C. Cell lysates were sonicated, and the resulting disrupted DNA was chromatin immunoprecipitated (ChIP) with Sp1 antibody or control IgG as described in MATERIALS AND METHODS. After reversal of cross-linking, target DNA was amplified using MUC1 primers with 40 cycles of PCR. Each data point represents the mean Ϯ SE (n ϭ 3). Data are representative of 3 experiments. *P Ͻ 0.05, significantly different from vehicle control. inflammation, the manner in which inflammation is controlled is less clearly understood. It is known, however, that IL-10 plays an important role in resolving inflammation and is considered the major anti-inflammatory cytokine in the lung (36) . The relationship among IL-10, TNF-␣, and MUC1 in controlling respiratory inflammatory responses, however, remains to be clarified. In 1999, Skerrett et al. (40) reported that TNFR1 null mice treated intranasally with P. aeruginosa showed significantly increased inflammation compared with wild-type mice, as measured by enhanced bacterial clearance, increased numbers of neutrophils in bronchoalveolar lavage fluid (BALF), and higher levels of TNF-␣ in BALF. Interestingly, these phenotypes were identical to those described in our prior report (25) following experimental P. aeruginosa lung infection of Muc1 knockout mice. In that study, we demonstrated that MUC1/Muc1 expression by human/mouse airway epithelial cells was associated with an anti-inflammatory response, mediated through cross talk with Toll-like receptor 5 (TLR5).
Based on the result of the current study demonstrating that exogenous TNF-␣ stimulated MUC1 production, one possible explanation for the fact that TNFR1 knockout mice display phenotypes similar to those of Muc1 null mice following P. aeruginosa infection is that TNFR1 knockout mice failed to upregulate MUC1 levels following P. aeruginosa infection. Because NE activates TNF-␣ expression by cultured lung epithelial cells (37), we theorize that release of the protease from infiltrating neutrophils is an initial event that is responsible for an early proinflammatory response following P. aeruginosa infection mediated, in part, by TNF-␣. Subsequently, TNF-␣ induces MUC1 expression to downregulate inflammation, possibly through MUC1's ability to block TLR signaling (25) and/or to stimulate IL-10 production by airway dendritic cells (8, 28) . Moreover, IL-10 inhibits TNF-␣ production (10), suggesting a feedback mechanism may operate to control the excessive and prolonged inflammatory effect by TNF-␣. Thus the interactions among TNF-␣, MUC1, and IL-10 may play a crucial role controlling the balance between proinflammatory and anti-inflammatory responses during P. aeruginosa lung infection. Further studies in our laboratory are directed at elucidating the functional relationships between these three key airway effector molecules.
